The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Outcomes of HMA+ven in patients with MDS: a multicenter retrospective analysis
In this video, Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, presents results from a large multicenter, retrospective real-world analysis evaluating the clinical utilization and outcomes of hypomethylating agents in combination with venetoclax (HMA+ven) in high-risk patients with myelodysplastic syndromes (MDS). Dr Guru Murthy reveals that HMA+ven was relatively tolerable and effectively administered in the outpatient setting with minimal tumor lysis syndrome (TLS). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
